Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Lunetta

Showing results (91-100 of 167) with videos related to

Pageof 17
Sort By:
Scientific Reports|January 22, 2021
Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosisElisa Conti, Gessica Sala, Susanna Diamanti, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 14, 2015
Extrapyramidal and cognitive signs in amyotrophic lateral sclerosis: A population based cross-sectional studyElisabetta Pupillo, Elisa Bianchi, Paolo Messina, et al.
Journal of the Neurological Sciences|August 4, 2020
Muscle MRI in two SMA patients on nusinersen treatment: A two years follow-upAndrea Barp, Elena Carraro, Emilio Albamonte, et al.
Journal of Neurology|August 19, 2021
A preliminary comparison between ECAS and ALS-CBS in classifying cognitive-behavioural phenotypes in a cohort of non-demented amyotrophic lateral sclerosis patientsLucia Catherine Greco, Andrea Lizio, Jacopo Casiraghi, et al.
Human Brain Mapping|February 3, 2016
Structural brain correlates of cognitive and behavioral impairment in MNDFederica Agosta, Pilar M Ferraro, Nilo Riva, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 26, 2020
Which are the factors influencing NIV adaptation and tolerance in ALS patients?Massimo Russo, Carmen Bonanno, Claudia Profazio, et al.
BMJ Open|March 27, 2020
G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial)Paolina Salamone, Giuseppe Fuda, Federico Casale, et al.
Neurobiology of Aging|December 25, 2017
ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosisSerena Lattante, Maria Grazia Pomponi, Amelia Conte, et al.
Neurobiology of Aging|July 2, 2017
Structural and functional brain signatures of C9orf72 in motor neuron diseaseFederica Agosta, Pilar M Ferraro, Nilo Riva, et al.
Journal of Neurology|May 27, 2024
Update on recent advances in amyotrophic lateral sclerosisNilo Riva, Teuta Domi, Laura Pozzi, et al.
Pageof 17

Showing results (91-100 of 167) with videos related to

Sort By:
Pageof 17
Scientific Reports|January 22, 2021
Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosisElisa Conti, Gessica Sala, Susanna Diamanti, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 14, 2015
Extrapyramidal and cognitive signs in amyotrophic lateral sclerosis: A population based cross-sectional studyElisabetta Pupillo, Elisa Bianchi, Paolo Messina, et al.
Journal of the Neurological Sciences|August 4, 2020
Muscle MRI in two SMA patients on nusinersen treatment: A two years follow-upAndrea Barp, Elena Carraro, Emilio Albamonte, et al.
Journal of Neurology|August 19, 2021
A preliminary comparison between ECAS and ALS-CBS in classifying cognitive-behavioural phenotypes in a cohort of non-demented amyotrophic lateral sclerosis patientsLucia Catherine Greco, Andrea Lizio, Jacopo Casiraghi, et al.
Human Brain Mapping|February 3, 2016
Structural brain correlates of cognitive and behavioral impairment in MNDFederica Agosta, Pilar M Ferraro, Nilo Riva, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 26, 2020
Which are the factors influencing NIV adaptation and tolerance in ALS patients?Massimo Russo, Carmen Bonanno, Claudia Profazio, et al.
BMJ Open|March 27, 2020
G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial)Paolina Salamone, Giuseppe Fuda, Federico Casale, et al.
Neurobiology of Aging|December 25, 2017
ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosisSerena Lattante, Maria Grazia Pomponi, Amelia Conte, et al.
Neurobiology of Aging|July 2, 2017
Structural and functional brain signatures of C9orf72 in motor neuron diseaseFederica Agosta, Pilar M Ferraro, Nilo Riva, et al.
Journal of Neurology|May 27, 2024
Update on recent advances in amyotrophic lateral sclerosisNilo Riva, Teuta Domi, Laura Pozzi, et al.
Pageof 17